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ABSTRACT
Background    Although the clinicopathologic features 
and prognosis of Borrmann type advanced gastric 
cancer has been well characterized, those of advanced 
gastric cancer simulating early gastric cancer  (AGC 
simulating EGC) still remains unclear. 
Methods    We reviewed 1985 gastric cancer patients 
who had undergone gastrectomy at our hospital to deter-
mine the clinicopathologic characteristics, susceptible 
sites for lymph node metastasis, and prognosis of AGC 
simulating EGC in comparison with Borrmann type ad-
vanced gastric cancer.
Results    Among 102 patients with AGC simulating 
EGC, 100 patients (98%) had tumors with depressed 
type appearance. The frequencies of serosal invasion, 
lymph node metastasis, lymphatic vessel invasion, blood 
vessel invasion, and liver metastasis were significantly 
lower in AGC simulating EGC than in Borrmann type 
tumors. The prognosis of AGC simulating EGC was sig-
nificantly better than that of the Borrmann type tumors. 
Multivariate analysis indicated that the gross appearance 
was an independent prognostic factor.  In patients with 
AGC simulating EGC which invaded to the the muscu-
laris propria (MP), most lymph node metastasis was re-
stricted with the perigastric lymph nodes (1st-titer lymph 
nodes) and lymph node metastasis to 2nd-titer lymph 
nodes was only observed at station 8a. 
Conclusion    AGC simulating EGC is less advanced in 
comparison with Borrmann type advanced gastric can-
cer. Based on the results of susceptible sites for lymph 
node metastasis in the current study, limited lymph node 
dissection could be indicated for AGC simulating EGC 
whose depth of invasion is MP. 
 




Gastric cancer is one of the most common cancers in 
Asia and its mortality still ranks second among all can-
cer deaths worldwide.1 In Japan, gastrectomy with D2 
lymph node dissection is performed safely and is widely 
accepted as a standard treatment for locally advanced 
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gastric cancer.2, 3 On the other hand, Japanese gastric 
cancer treatment guidelines recommend gastrectomy 
with limited lymph node dissection as a curative treat-
ment for early gastric cancers,4 since lower incidence of 
lymph node metastasis is expected in early gastric can-
cer.5, 6, 7, 8 The accurate diagnosis of tumor depth prior to 
surgery is important since surgeons must decide on the 
treatment strategy based on the preoperative findings. 
However, the accuracy of preoperative diagnosis of early 
gastric cancer is limited and has been reported as 92.4% 
to 95.4%.9, 10 This finding suggests that substantial num-
bers of patients who were clinically diagnosed early 
gastric cancer are actually advanced gastric cancer and 
might require D2 lymph node dissection as a curative 
treatment. Theoretically, additional surgery to achieve 
D2 lymph node dissection is required for patients with 
clinically early but pathologically advanced gastric 
cancer following gastrectomy with limited lymph node 
dissection. However, the feasibility of this additional sur-
gery has not been investigated thus far.
 The gross type of gastric cancer is classified into 6 
types, 0 to 5, according to the Japanese Classification of 
Gastric Cancer (JCGC).11 Types 1, 2, 3 and 4 are based 
on the Borrmann classification. Most advanced gastric 
cancers show Borrmann type appearance while most 
early gastric cancers show type 0 appearance. However, 
it was reported that some advanced cancers show type 0 
appearance like early gastric cancer, namely advanced 
gastric cancer simulating early gastric cancer (AGC 
simulating EGC).12 The clinicopathologic features and 
prognosis of Borrmann type advanced gastric cancer, 
especially Borrmann type 4 gastric cancer, has been 
well characterized thus far.13, 14, 15 However, the clini-
copathologic features and prognosis of AGC simulat-
ing EGC still remain unclear thus far. Of importance 
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is that AGC simulating EGC is likely to be clinically 
diagnosed as early gastric cancer prior to operation. 
As a result, limited lymph node dissection might be 
performed for those patients, which might be an insuffi-
cient treatment according to the Japanese gastric cancer 
treatment guidelines. On the other hand, there might be 
a difference in the 5-year survival rate and clinicopatho-
logical characteristics, including susceptible site and the 
incidence of the lymph node metastasis, between AGC 
simulating EGC and Borrmann type advanced gastric 
cancer. Moreover, if AGC simulating EGC is associated 
with lower incidence of lymph node metastasis and bet-
ter prognosis, gastrectomy with limited lymph node dis-
section may provide a suitable curative treatment option. 
In the present study, we investigated the clinicopatho-
logical characteristics and long-term survival outcome 
of AGC simulating EGC and Borrmann type advanced 
gastric cancer. Furthermore, the susceptible sites for 
lymph node metastasis in AGC simulating EGC were 
also evaluated to clarify whether limited lymph node 




This study examined 1985 consecutive gastric adeno-
carcinoma patients, 1266 male and 719 female, who had 
undergone gastrectomy at our institution between Janu-
ary 1975 and December 2000. Ages ranged between 
20 and 93 years with an average age of 62 years. The 
clinicopathological findings were determined according 
to JCGC.11 All had undergone distal partial gastrectomy, 
proximal partial gastrectomy or total gastrectomy with 
regional lymph node dissection to group 1 (D1), group 2 
(D2) or group 3 (D3).
 At the time of analysis, the median follow-up for 
1074 survivors was 108 months. Of the 911 deaths, 560 
were related to recurrence of gastric cancer, 57 were due 
to another malignancy and 279 were due to another dis-
ease or accident. The cause of death was unknown in 15 
patients. 
 AGC simulating EGC was defined as advanced gas-
tric cancer with early gastric cancer-like gross appear-
ance (type 0). According to JCGC, the endoscopic classi-
fication is as follows: elevated type, I (protruded) and IIa 
(superficial elevated); flat type, IIb; or depressed type, 
IIc (superficial depressed) and III (excavated). There are 
also mixed types of tumor, such as IIc + III, IIa + IIc, 
etc. The first designation indicates the dominant macro-
scopic type in the description of a mixed type of tumor. 
When the elevated lesion had a depressed area, as in the 
IIa + IIc type, we classified it as a depressed type tumor 
in the present study.
 
Table 1. Clinicopathologic characteristics of AGCs according to gross type appearance
Variable         AGC simulating EGC Localized type Infiltrated type 
 (n = 102) (n = 303) (n = 590)
Age, mean (SD), yr  58.9 (12.5)*  65.6 (11.1)† 60.5 (12.5) 
Size, mean (SD), cm  4.7 (2.3)*‡   6.6 (3.0)† 9.7 (4.7) 
Gender Male 62 (60.8%)  194 (64.0%) 354 (60.0%) 
 Female 40 (39.2%) 109 (36.0%) 236 (40.0%)
Histology Differentiated 33 (32.4%)* 151 (49.8%)† 144 (24.4%)
 Undifferentiated 69 (67.6%) 152 (50.2%) 446 (75.6%)
Serosal invasion Absent 72 (70.6%)*‡    127 (41.9%)†  104 (17.6%) 
 Present 30 (29.4%) 176 (58.1%) 486 (82.4%)
Lymph node metastasis Absent 64 (62.7%)*‡    89 (29.4%)†  117 (19.8%) 
 Present 38 (37.3%) 214 (70.6%) 473 (80.2%)
Lymphatic vessel invasion Absent 48 (47.1%)*‡    67 (22.1%)  107 (18.1%) 
 Present 54 (52.9%) 236 (77.9%) 483 (81.9%)
Blood vessel invasion Absent 69 (67.6%)*‡    93 (30.7%)† 230 (39.0%)
 Present 33 (32.4%) 210 (69.3%) 360 (61.0%)
Peritoneal metastasis Absent 100 (98.0%)‡ 291 (96.0%)† 474 (80.3%)
 Present 2 (2.0%) 12 (4.0%) 116 (19.7%)
Liver metastasis Absent 96 (94.1%)*‡  256 (84.5%) 509 (86.3%)
 Present   6 (5.9%)   47 (15.5%)  81 (13.7%)
Curability Curative 97 (95.1%)*‡ 255 (84.2%)† 400 (67.8%)
 Non-curative 5 (4.9%) 48 (15.8%) 190 (32.2%)
 AGC simulating ECG, advanced gastric cancer simulating early gastric cancer; differentiated, papillary or tubular adenocarcinoma; un-
differentiated, poorly differentiated or mucinous adenocarcinoma, or signet-ring cell carcinoma. 
* AGC simulating EGC versus localized type; P < 0.05.
† Infiltrated type versus localized type; P < 0.05.




The significance of the differences among the means 
was determined by the Mann-Whitney U test. Survival 
curves were calculated according to the Kaplan-Meier 
method. Survival data shown in the current study were 
for cancer-specific survival. To this end, deaths not from 
gastric cancer were considered as lost to follow-up as of 
time of death. Differences between survival curves were 
examined with the log rank test. Multivariate analysis of 
prognostic factors related to survival was performed us-
ing the Cox proportional hazards model and a step-wise 
procedure. The accepted level of significance was P < 
0.05. Stat View software (Abacus Concepts, Berkeley, 
CA) was used for all statistical analyses.
  
RESULTS
There were 102 patients (9.4%) with AGC simulating 
EGC, 30 patients (2.8%) with Borrmann type 1, 273 
patients (25.3%) with Borrmann type 2, 396 patients 
(36.6%) with Borrmann type 3 and 194 patients (17.9%) 
with Borrmann type 4 tumors. Borrmann type 1 and 
2 tumors were considered localized type (L-type) and 
Borrmann type 3 and 4 were considered infiltrative type 
(I-type) in the analysis. Among 102 patients with AGC 
simulating EGC, IIa was observed in 2 patients, IIa + 
IIc in 10 patients, IIc in 74 patients and IIc + III in 16 
patients, indicating that 100 patients (98%) with AGC 
simulating EGC showed depressed type tumors.
 Table 1 shows the correlation between gross appear-
ance and clinicopathologic factors. Patients with AGC 
simulating EGC were significantly younger than those 
with L-type tumors. The tumor size of AGC simulating 
EGC was significantly smaller than that of L-type and 
I-type tumors. Undifferentiated carcinoma was more 
Fig. 1. The 5-year survival rates in early gastric cancer with inva-
sion to SM, AGC simulating EGC, L-type and I-type tumors, re-
spectively. The prognosis of AGC simulating EGC is significantly 
better than that of L-type and I-type, and significantly worse than 
that of early gastric cancer with invasion to SM. AGC simulating 
EGC, advanced gastric cancer simulating early gastric cancer; I-
type, infiltrative type; L-type, localized type; SM, submucosa.
Table 2. Association of various factors with survival determined by the Cox proportional hazards model and a 
stepwise procedure
 Prognostic factor P value Hazard ratio 95% CI 
 Age*  0.0013 1.013 1.005–1.021
Tumor size*  0.0004 1.036 1.016–1.056
Depth of invasion (t2–t4)†   < 0.0001  1.484 1.261–1.748
Lymph node metastasis (n0–n3)‡   < 0.0001  1.460 1.340–1.591
Lymphatic vessel invasion (ly0–ly3)§  0.0108 1.118 1.026–1.218
Peritoneal metastasis (absent or present)  < 0.0001 1.332 1.186–1.496
Liver metastasis  (absent or present)  < 0.0001  1.446 1.263–1.656
Curability  (curative or noncurative)    < 0.0001  0.358 0.278–0.460
Gross appearance AGC simulating EGC (versus I-type) 0.0014 0.437 0.263–0.727
 L-type (versus I-type)   0.0007 0.677 0.540–0.849
  AGC simulating EGC, advanced gastric cancer simulating early gastric cancer; CI, confidence interval; I-type, infiltrative type; L-type, 
localized type.
*Continuous variable.
†t2, tumor has invaded the muscularis propria or the subserosa; t3, penetrating the serosa; t4, invading adjacent organs.
‡n0, no regional lymph node metastasis; n1, n2 and n3, metastasis in groups 1, 2 and 3 lymph nodes, respectively.
§Lymphatic invasion: ly0–ly3, grade of lymphatic vessel invasion.
frequently observed in AGC simulating EGC than in L-
type tumors. The frequency of serosal invasion, lymph 
node metastasis, lymphatic vessel invasion, blood vessel 
invasion and liver metastasis were significantly lower in 
AGC simulating EGC than in L-type and I-type tumors. 
Peritoneal metastasis was less frequently observed in 
AGC simulating EGC than in I-type tumors. Moreover, 
a curative operation could be performed more frequently 
in patients with AGC simulating EGC than in those with 
L-type and I-type tumors. 
 The 5-year survival rates were 87.8%, 60.7% and 
32.4% in AGC simulating EGC, L-type and I-type 
tumors, respectively (Fig. 1). The prognosis of AGC 
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simulating EGC was significantly better than that of L-
type and I-type. There were 448 early gastric cancer 
patients with invasion to the submucosa during the same 
period. The 5-year survival rate of these patients was 
97.9%, which was significantly better than that of AGC 
simulating EGC (Fig. 1). To determine whether AGC 
simulating EGC is an independent prognostic factor in 
advanced gastric cancer, multivariate analysis using Cox 
proportional hazard model and a stepwise procedure 
was applied. Multivariate analysis indicated that the 
gross appearance was an independent prognostic factor 
as well as age, tumor size, depth of invasion, lymph node 
metastasis, lymphatic vessel invasion, peritoneal metas-
tasis, liver metastasis and curability (Table 2). 
 With regard to the mode of recurrence, peritoneal 
recurrence (7.8%) was the most frequent site, followed 
by hematogenous (5.9%) and lymph node recurrence 
(1.7%) in patients with AGC simulating EGC (Fig. 2). 
Peritoneal recurrence (34.7%) occurred significantly 
more than hematogenous (13.7%) or lymph node recur-
rence (10.5%) in patients with I-type advanced cancer. 
On the other hand, hematogenous recurrence (15.5%) 
occurred significantly more than peritoneal (8.9%) or 
lymph node recurrence (7.6%) in patients with L-type 
advanced cancer.
 Figure 3 shows the frequency of lymph node me-
tastasis of AGC simulating EGC according to the depth 
of invasion. In patients with tumors which invade the 
muscularis propria (MP), most lymph node metastasis 
was restricted with the perigastric lymph nodes (1st-titer 
lymph nodes) and lymph node metastasis to 2nd-titer 
lymph nodes was only observed at station 8a. On the 
other hand, lymph node metastasis to 2nd-titer lymph 
nodes was observed at stations 9, 11 and 12a as well as 
station 8a in patients with tumor that invaded the subse-
rosa (SS) or penetrated the serosa (SE).  
 
Fig. 3. The frequency of lymph node 
metastasis at each lymph node station 
according to the depth of invasion. In 
patients with MP tumors, most lymph 
node metastasis was restricted with the 
perigastric lymph nodes (1st-titer lymph 
nodes) and lymph node metastasis to 2nd-
titer lymph nodes was only observed at 
station 8a. On the other hand, lymph node 
metastasis to 2nd-titer lymph nodes was 
observed at stations 9, 11 and 12a as well 
as station 8a in patients with SS and SE 
tumors.  MP, muscularis propria; SE, se-
rosa; SS, subserosa. 
Fig. 2. The site of recurrence in each type of tumor.  Peritoneal 
recurrence is the most frequent site, followed by hematogenous 
and lymph node sites in patients with either AGC simulating EGC 
or I-type tumors. On the other hand, hematogenous recurrence 
is the most frequent site, followed by peritoneal or lymph node 
recurrence in patients with L-type tumors. AGC simulating EGC, 
advanced gastric cancer simulating early gastric cancer; I-type, 
infiltrative type; L-type, localized type. 
DISCUSSION
The classification of advanced gastric cancer into 4 gross 
morphological types by Borrmann in 192616 is presently 
accepted by many surgeons throughout the world.17 This 
reflects unique characteristics of each type of tumor in 
gastric cancer. For instance, Borrmann type 4 gastric 
cancer can be characterized by a high incidence of poor-
ly differentiated tumor and peritoneal metastasis, and 
extremely poor prognosis.14, 15 Chen et al. reported that 
Borrmann type 1 gastric cancer could be characterized 
by its presence in the upper stomach, a high incidence of 
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intestinal type, a less advanced stage and good progno-
sis.13
 In the present study, we demonstrated that the fre-
quencies of serosal invasion, lymph node metastasis, 
lymphatic vessel invasion, blood vessel invasion and 
liver metastasis were significantly lower in AGC simu-
lating EGC than in L-type and I-type tumors. Peritoneal 
metastasis was less frequently observed in AGC simulat-
ing EGC than in I-type tumors. Furthermore, the prog-
nosis of AGC simulating EGC was significantly better 
than that of L-type and I-type tumors. These results 
indicate that AGC simulating EGC is less advanced in 
comparison with Borrmann type advanced gastric can-
cer. On the other hand, the dominant histological type of 
AGC simulating EGC was undifferentiated type, which 
is consistent with a previous report.12 With regard to the 
site of recurrence, peritoneal recurrence was the most 
frequent site, followed by hematogenous and lymph 
node sites in patients with AGC simulating EGC. This 
trend was similar to I-type AGC although the recur-
rence rate was lower in AGC simulating EGC than in I-
type AGC. Therefore, AGC simulating EGC has similar 
clinicopathologic characters to I-type AGC, indicating 
the possibility that AGC simulating EGC might progress 
to I-type AGC.
 With regard to the differences in biological charac-
ter, Ichiyoshi et al. demonstrated that the incidence of 
p53 overexpression in Borrmann type cancer was higher 
than that in AGC simulating EGC in gastric cancer in-
vading the MP. They also demonstrated that the prolif-
erating activity measured by MIB-1 labeling percentage 
was higher in Borrmann type cancer than in AGC simu-
lating EGC.18 These results indicate that Borrmann type 
cancer and AGC simulating EGC are distinct in their 
inherent biological nature.
 The extent of lymph node dissection is different 
depending on the depth of invasion according to the 
Japanese gastric cancer treatment guidelines.4 In fact, 
lymph node dissection of group 1 and group 2 nodes 
(D2) has been a standard procedure for advanced gastric 
cancer in Japan. On the other hand, lesser lymph node 
dissection is carried out for early gastric cancer patients 
to reduce postgastrectomy disorders, because only a 
few patients have lymph node metastasis. Furthermore, 
laparoscopy-assisted gastrectomy (LAG) has increas-
ingly been performed as a minimally invasive surgical 
treatment option for the treatment of early gastric cancer 
in Japan.19 The treatment strategy must be decided based 
on the preoperative findings. The problem is that the ac-
curacy of preoperative diagnosis of early gastric cancer 
is limited. Although intraoperative findings indicating 
signs of advanced gastric cancer are often helpful in 
changing treatment strategies, it is generally difficult to 
distinguish pT1 and pT2 gastric cancer, particularly dur-
ing laparoscopic surgery in which manipulation of the 
tumor is limited. As a result, we occasionally encounter 
a situation in which the results of a pathological exami-
nation of a resected specimen indicate T2 advanced gas-
tric cancer, despite a clinical diagnosis of T1 gastric can-
cer. Of importance is that AGC simulating EGC can be 
understaged endoscopically and by gross examination, 
indicating that LAG with limited lymph node dissection 
might be performed for those patients. Theoretically, 
additional surgery to achieve D2 lymph node dissection 
is required for those patients, followed by gastrectomy 
with limited lymph node dissection. In patients with MP 
tumors, however, most lymph node metastasis was re-
stricted with the perigastric lymph nodes (1st-titer lymph 
nodes) and lymph node metastasis to 2nd-titer lymph 
nodes was only observed at station 8a in the present 
study. On the other hand, lymph node metastasis to 2nd-
titer lymph nodes was observed at stations 9, 11 and 12a 
as well as station 8a in patients with SS and SE tumors. 
Considering better prognosis of AGC simulating EGC 
than that of Borrmann type advanced gastric cancer and 
results of susceptible sites for lymph node metastasis, 
limited lymph node dissection could be indicated for 
AGC simulating EGC whose depth of invasion is MP.
In conclusion, AGC simulating EGC is less advanced 
than Borrmann type advanced gastric cancer. Based on 
the results of susceptible sites for lymph node metastasis 
in the present study, limited lymph node dissection could 
be indicated for AGC simulating EGC whose depth of 
invasion is MP.
The authors declare no conflict of interest.
REfERENCES
 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 
2002. CA Cancer J Clin. 2005;55:74-108. PMID: 15761078.
 2 Kodera Y, Schwarz RE, Nakao A. Extended lymph node 
dissection in gastric carcinoma: where do we stand after 
the Dutch and British randomized trials? J Am Coll Surg. 
2002;195:855-64. PMID: 12495318.
 3 Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric 
cancer surgery in Japan and its limits of radicality. World J 
Surg. 1987;11:418-25. PMID: 3630186.
 4 Japanese Gastric Cancer Association. Japanese gastric cancer 
treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-
23. PMID: 21573742.
 5 Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, 
Shimoda T, et al. Incidence of lymph node metastasis from 
early gastric cancer: estimation with a large number of cases 
at two large centers. Gastric Cancer. 2000;3:219-25. PMID: 
11984739.
 6 Nakajima T. Gastric cancer treatment guidelines in Japan. 
Gastric Cancer. 2002;5:1-5. PMID: 12021853.
78
H. Saito et al.
 7 Seto Y, Shimoyama S, Kitayama J, Mafune K, Kaminishi 
M, Aikou T, et al. Lymph node metastasis and preoperative 
diagnosis of depth of invasion in early gastric cancer. Gastric 
Cancer. 2001;4:34-8. PMID: 11706625.
 8 Yamao T, Shirao K, Ono H, Kondo H, Saito D, Yamaguchi H, 
et al. Risk factors for lymph node metastasis from intramuco-
sal gastric carcinoma. Cancer. 1996;77:602-6. PMID: 8616749.
 9 Sano T, Okuyama Y, Kobori O, Shimizu T, Morioka Y. Early 
gastric cancer. Endoscopic diagnosis of depth of invasion. Dig 
Dis Sci. 1990;35:1340-4. PMID: 2226095.
10 Yanai H, Matsumoto Y, Harada T, Nishiaki M, Tokiyama H, 
Shigemitsu T, et al. Endoscopic ultrasonography and endosco-
py for staging depth of invasion in early gastric cancer: a pilot 
study. Gastrointest Endosc. 1997;46:212-6. PMID: 9378206.
11 Japanese Gastric Cancer Association. Japanese Classification 
of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 
2011;14:101-12. PMID: 21573743.
12 Mori M, Adachi Y, Nakamura K, Kuroiwa S, Enjoji M, 
Sugimachi K. Advanced gastric carcinoma simulating early 
gastric carcinoma. Cancer. 1990;65:1033-40. PMID: 2297652.
13 Chen JH, Wu CW, Lo SS, Li AF, Hsieh MC, Shen KH, et al. 
Lymph node metastasis as a single predictor in patients with 
Borrmann type I gastric cancer. Hepatogastroenterology. 
2007;54:981-4. PMID: 17591108.
14 Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological fea-
tures of patients with Borrmann type IV gastric carcinoma. 
ANZ J Surg. 2002;72:739-42. PMID: 12534387.
15 Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, 
Sugimachi K, et al. Clinicopathologic study of patients 
with Borrmann type IV gastric carcinoma. J Surg Oncol. 
1995;58:112-7. PMID: 7844980.
16 Borrmann R. Geschwülste Des Magens und Des Duodenums. 
Vol. I. Berlin: Springer; 1926.
17 Borchard F. Classification of gastric carcinoma. Hepatogastro-
enterology. 1990;223-32. PMID: 2187787.
18 Ichiyoshi Y, Tomoda M, Tomisaki S, Oda S, Ohno S, Maehara 
Y, et al. Macroscopic appearance and biological character of 
gastric cancer invading the muscularis propria. Hepatogastro-
enterology. 1996;43:553-9. PMID: 8799394.
19 Shiraishi N, Yasuda K, Kitano S. Laparoscopic gastrectomy 
with lymph node dissection for gastric cancer. Gastric Cancer. 
2006;9:167-76. PMID: 16952034.
